Skip to content

Comparison Between Manta and Prostar Closure Devices

Use of the Closure Device in Patient With Percutaneous Transfemoral Aortic Valve Replacement

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05662748
Enrollment
250
Registered
2022-12-22
Start date
2020-01-20
Completion date
2021-03-30
Last updated
2022-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Keywords

Closure

Brief summary

Use of the closure device in patient with percutaneous transfemoral aortic valve replacement

Detailed description

The advent of endovascular, transcatheter aortic valve replacement (TAVR), and mechanical circulatory support has offered new, minimally invasive therapeutic options that are rapidly becoming standard of care. These percutaneous transfemoral interventions require large-bore catheters and have created challenges for femoral arterial access management. Current approaches include surgical cut-down with arterial puncture under direct vision, and suture-based pre-closure. Surgical cut-down is associated with longer procedural time, increased patient discomfort, deeper anesthesia, risk of wound complications including infection, and slower ambulation. The pre-closure technique overcomes many of the disadvantages of surgical cut-down but can be technically demanding, time consuming, and associated with a significant failure rate. Recent randomized TAVR trials have reported major vascular complications in 6% to 8% . Furthermore, a study on the 2 suture-based closure techniques for management of TAVR access reported a 20% vascular complication rate despite being used by experienced operators . Currently, the majority of access site complications result from failed arteriotomy closure . The percutaneous MANTA Vascular Closure Device (VCD) (Essential Medical Inc., Malvern, Pennsylvania) is a novel collagen-based technology dedicated to closure of largebore arteriotomies . The MANTA VCD underwent prospective multicenter evaluation for Conformitä Europäenne (CE) mark approval in the first detailed report of outcomes achieved with a dedicated large-bore vascular closure device Contrary to the aforementioned TAVR procedures, mechanical circulatory support therapy can be extended up to several days on the intensive care ward. Data on such delayed closure with is lacking. This registry is therefore aimed to document the initial experiences of delayed closure of a femoral large bore access with vascular closure devices in patients with an TAVR device.

Interventions

DEVICETransfemoral aortic valve replacement

aortic valve replacement

Sponsors

RWTH Aachen University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient scheduled for treatment with the TAVR device 2. Decision to use the Manta or the Prostar closure device on a clinical base by the treating physician 3. Signed informed consent

Exclusion criteria

* Male or female aged \< 18 2. Pregnant and lactating females 3. Patient has been committed to an institution by legal or regulatory order

Design outcomes

Primary

MeasureTime frameDescription
Safety endpoints during index hospitalisation ( death )2018-2020death
Safety endpoints during index hospitalisation2018 - 2020Major vascular complications,
Safety endpoints during index hospitalisation ( bleeding)2018-2020life-threatining-, major bleeding

Secondary

MeasureTime frameDescription
efficacy endpoints during index hospitalisation ( bail-out )2018-2020need for stent-graft
efficacy endpoints during index hospitalisation - (hemotasis)2018-2020hemotasis in angiogram
efficacy endpoints during index hospitalisation ( device failure)2018-2020device failure

Other

MeasureTime frameDescription
preperation time2018-2020preperation time for closure

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026